13d
CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink
Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has ...
Rezolute ( (RZLT)) has shared an announcement. On January 7, 2025, Rezolute reported detailed observations from its Phase 3 sunRIZE trial in congenital hyperinsulinism, noting that although the study ...
IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the Baxter IV fluids crisis have shown that ...
13d
CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference
CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus on expanding its pipeline while integrating the recently acquired Melinta ...
The role of nutrition in patient care became a part of mainstream medicine at about the end of the 1960s, with the publication of several papers that showed a benefit of nutritional support in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results